Beebe and The Delaware Cancer Registry
The Delaware Cancer Registry presented Beebe Healthcare's Tumor Registry Department with a Certificate of Achievement for "The Most Timely and Complete Reporting in 2007."
Helen Moody, CTR (seated), Ann Moore, LPN, CTR (left), and Sue Cadwallader, CTR, enter Beebe's patient data into the Tumor Registry so it can be compared with state and national outcomes.
The Delaware Cancer Registry is a cancer information center that collects data about new cancer cases, cancer treatment, and cancer deaths for the entire state of Delaware. The Registry data offers numerous benefits, including the monitoring of trends, promoting scientific research to increase survival, educating the public, providing information for policy planning in cancer prevention and control, plus sharing and comparing cancer data with other states and the Performance Improvement National Cancer Center Data Base. The national organization collects information nationwide to monitor cancer trends, plan cancer prevention and control programs, and help set priorities for allocating health resources and advance medical research.
The Beebe Healthcare Tumor Registry is the cornerstone of an Approved Cancer Program that is recognized by the American College of Surgeons Commission on Cancer. It collects data on cancer incidence, type, stage at diagnosis, treatment, and survival, and submits the data to the Delaware Central Registry and to the National Cancer Center Data Base. The Beebe Healthcare Tumor Registry has a follow-up rate of 98.2 percent of Tunnell Cancer Center patients. The standard for the Commission on Cancer is 90 percent. Members of the department are Helen Moody, CTR (certified tumor registrar), Susan Cadwallader, CTR, and Ann Moore, LPN.
Data on cancer incidence, type, stage at diagnosis, treatment, and survival is collected by the Cancer Registry and reported to the Delaware State Central Registry. Registry data is also submitted to the National Cancer Data Base, which uses this information to monitor cancer trends, plan cancer prevention programs, help set priorities, and advance medical research efforts.
Cases Diagnosed since reference date 1995 through September 2010
Total patients in registry since reference date = 7,828
Less benign and borderline (except CNS > 2003) = 6
Less carcinoma in situ cervix = 10
Less all basal and squamous cell carcinoma of skin (except State III and IV before 2003) = 10
Less foreign residents = 10
Less patients over 100 years of age not contacted in 12 months = 3
Less nonanalytic class of case = 439
Less class of case 0 after 2005 = 194
Subtotal = 7,156
Less number expired 3,139 Subtotal (number living) = 4,017
Number living with current follow-up (within 15 months) = 3,310
Patients lost to follow-up = 707
Percent of successful follow-up rate 90.1%
Cases Diagnosed within 5 years through September 2011
Total patients in registry since reference date = 3,116
Less benign and borderline (except CNS > 2003) = 1
Less carcinoma in situ cervix = 1
Less all basal and squamous cell carcinoma of skin (except Stage III and IV before 2003) = 1
Less foreign residents = 0
Less patients over 100 years of age not contacted in 12 months = 1
Less nonanalytic class of case = 54
Less class of case 0 after 2005 = 155
Subtotal = 2,903
Less number expired = 868
Subtotal (number living) = 2,035
Number living with current follow-up (within 15 months) = 1,855
Patients lost to follow-up = 180
Percent of successful follow-up rate = 93.8%
Source: Beebe Healthcare, Tumor Registry, RMCDS database cancer program